Human CGRPR&RAMP1 Full Length Heterodimer Protein (VLP)

Customer Reviews
Cat. No. / Size
Price
Qty
CG1-H52P6-20ug
$620.00
CG1-H52P6-100ug
$1235.00
CG1-H52P6-500ug (250ug X 2)
$4305.00
ETA of in-stock products:2 business days

Product Details

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    CGRPR & RAMP1

  • Source

    Human CGRPR&RAMP1 Full Length Heterodimer Protein (VLP) (CG1-H52P6) is expressed from human 293 cells (HEK293). It contains AA Glu 23 - Asn 461 (CGRPR) & Cys 27 - Val 148 (RAMP1) (Accession # Q16602-1 (CGRPR) & O60894-1 (RAMP1)).

    Predicted N-terminus: Asp & Trp

  • Molecular Characterization

    *The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SEC-HPLC.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SEC-HPLC

    CGRPR & RAMP1 SEC-HPLC

    The purity of Human CGRPR&RAMP1 Full Length Heterodimer Protein (VLP) (Cat. No. CG1-H52P6) was greater than 95% as determined by SEC-HPLC.

  • Bioactivity-ELISA

     CGRPR & RAMP1 ELISA

    Immobilized Human CGRPR&RAMP1 Full Length Heterodimer Protein (VLP) (Cat. No. CG1-H52P6) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CGRPR antibody, human IgG with a linear range of 0.5-8 ng/mL (QC tested).

    Protocol
  • Identity-DLS

     CGRPR & RAMP1 DLS

    The mean peak Radius of VLP is 95-120 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

Customer Reviews
Writing Reviews

Background

The Calcitonin Gene-Related Peptide Receptor, a heterodimer of CALCRL and RAMP1. It is the primary mediator of migraine pain and neurogenic inflammation. Targeted monoclonal antibodies (erenumab, galcanezumab) and small molecule antagonists (gepants) represent a major therapeutic class for migraine prevention and acute treatment.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8